<DOC>
	<DOCNO>NCT01378143</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy use OCZ103-OS combination standard care second line treatment subject unresectable locally recurrent metastatic colorectal cancer .</brief_summary>
	<brief_title>Using OCZ103-OS Patients With Unresectable Locally Recurrent Metastatic Colorectal Cancer Undergoing Standard Chemotherapy</brief_title>
	<detailed_description>This single arm , open label study investigate safety efficacy use OCZ103-OS combination standard therapy ( mFOLFOX6 FOLFIRI ) second line treatment subject unresectable locally recurrent metastatic colorectal cancer .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>1 . Histologically cytologically proven diagnosis adenocarcinoma colon/rectum evidence ( 1 ) unresectable , locally recurrent , ( 2 ) metastatic disease . 2 . Failure firstline therapy ( 5Fubased therapy +/ bevacizumab ) metastatic colorectal cancer . 3 . At least one ( 1 ) unidimensionally measurable lesion ( spiral CT scan ) . 4 . 18 year age old . 5 . ECOG performance status 0 , 1 2 . 6 . Serum aspartate transaminase ( AST ) , serum alanine transaminase ( ALT ) , serum alkaline phosphatase ( ALP ) ≤ 2.5 x upper limit normal ( ULN ) , AST , ALT , ALP ≤ 5 x ULN liver function abnormality due underlying malignancy 7 . Total serum bilirubin ≤ 1.5 x ULN 8 . Lipase amylase within normal limit abnormal limit deem clinically significant . 9 . Absolute neutrophil count ( ANC ) ≥ 1500/µL ( 1.5 x 10e9/L ) 10 . Platelets ≥ 100,000/µL ( 100 x 10e9/L ) 11 . Hemoglobin ≥ 90 g/L 12 . Serum creatinine ≤ 1.5 x ULN calculate creatinine clearance ≥ 60 ml/min . The CockcroftGault formula use follow : eCcr= ( 140age ) x Mass ( kilogram ) x Constant/Serum Creatinine ( µmol/L ) Where Constant 1.23 men 1.04 woman . 13 . Normal abnormal ECG . If ECG show abnormality , must deem clinically significant . 14 . Signed date Informed Consent Form indicate subject ( legally acceptable representative ) inform pertinent aspect trial prior enrollment . 15 . Willingness ability comply schedule visit , treatment plan , laboratory test , trial procedure . 16 . Life expectancy , opinion investigator , &gt; 3 month . Exclusion criteria 1 . Systolic Blood Pressure &lt; 100 mmHg ( deem clinically significant treat physician ) . 2 . Uncontrolled diabetes , severe renal impairment pancreatitis . 3 . Concomitant therapy investigational agent participation another clinical trial within 30 day prior enrollment . 4 . Any following condition : Ongoing cardiac dysrhythmias NCI CTCAE grade ≥ 2 ; atrial fibrillation grade ; QTc interval &gt; 450 msec male &gt; 470 msec female uncontrolled intercurrent illness , e.g . unstable angina ; severe coronary disease , ventricular arrhythmia , bradycardia &lt; 50 bpm ; history additional risk factor torsades de pointes ( e.g. , heart failure , hypokalemia family history Long QT Syndrome ) . 5 . Active uncontrolled bacterial infection . 6 . Concurrent use drug could prolong QT interval ( NB : pentamidine know induce torsades de pointes ) ( see Appendix II : List drug could prolong QT interval / also suggest refer follow link : http : //www.azcert.org/medicalpros/druglists/bycategory.cfm ) . 7 . Concurrent use nephrotoxic drug ( depend medical health status patient base judgment investigator ) , include limited aminoglycosides , ampho B , foscarnet cidofovir . 8 . Concurrent use drug Rifampine Lamivudine , since may associate pancreatitis . 9 . Prior malignancy colorectal cancer ( except adequately treat carcinoma situ cervix , nonmelanoma skin cancer localize prostate cancer undetectable PSA level ) unless prior malignancy diagnose definitively treat least five ( 5 ) year previously subsequent evidence recurrence . 10 . Clinically significant nonmalignant lung disease . 11 . History allergy hypersensitivity pentamidine . 12 . Pregnancy breastfeed . All female patient reproductive potential must negative pregnancy test ( serum urine ) prior first dose study medication . 13 . Severe acute chronic medical psychiatric condition , laboratory abnormality would impart , judgement investigator , excess risk associate trial participation study drug administration , judgement investigator , would make subject inappropriate entry trial . 14 . Use oral anticoagulant ( LMWH acceptable )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Pentamidine bi ( 2-hydroxyethanesulfonate )</keyword>
	<keyword>OCZ103-OS</keyword>
	<keyword>Standard Care</keyword>
</DOC>